Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer
Abstract Nowadays, chemotherapy and immunotherapy remain the major treatment strategies for Triple-Negative Breast Cancer (TNBC). Identifying biomarkers to pre-select and subclassify TNBC patients with distinct chemotherapy responses is essential. In the current study, we performed an unbiased Rever...
Saved in:
Main Authors: | Bohan Ning, Chang Liu, Ali Cem Kucukdagli, Jiuyi Zhang, Han Jing, Zhiqian Zhou, Yuwei Zhang, Ying Dong, Yunjia Chen, Hua Guo, Jia Xu |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-87315-x |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aurora kinase B inhibitor AZD1152: repurposing for treatment of lupus nephritis driven by the results of clinical trialsResearch in context
by: Yue Zhao, et al.
Published: (2025-02-01) -
Machine Learning-Assisted Drug Repurposing Framework for Discovery of Aurora Kinase B Inhibitors
by: George Nicolae Daniel Ion, et al.
Published: (2024-12-01) -
Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis
by: Qi Xu, et al.
Published: (2024-10-01) -
Unraveling the protein kinase C/NDRG1 signaling network in breast cancer
by: C. Saponaro, et al.
Published: (2024-12-01) -
AURKB affects the proliferation of clear cell renal cell carcinoma by regulating fatty acid metabolism
by: Yang Yang, et al.
Published: (2025-01-01)